Prelude posts Q2 net loss $30.4M; cash $255M funds operations into 2026

Prelude Therapeutics Inc

2023-Q1 EPS reported -$1.12

Net loss of $30.4M ($0.54/share) vs $27.4M ($0.58/share) in Q2 2022.
R&D expense rose to $25.0M from $21.3M YoY; G&A fell to $7.4M from $8.2M.
Cash, equivalents and marketable securities $255.0M; completed public offering raising $113M gross.
Pipeline milestones: CDK9 (PRT2527) confirmation dose target Q1 2024; SMARCA2 degrader IND early 2024.
Management expects cash runway into 2026; four lead programs on track for data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.